Literature DB >> 23596237

Direct comparison of Xpert MTB/RIF assay with liquid and solid mycobacterial culture for quantification of early bactericidal activity.

Xavier A Kayigire1, Sven O Friedrich, Amour Venter, Rodney Dawson, Stephen H Gillespie, Martin J Boeree, Norbert Heinrich, Michael Hoelscher, Andreas H Diacon.   

Abstract

The early bactericidal activity of antituberculosis agents is usually determined by measuring the reduction of the sputum mycobacterial load over time on solid agar medium or in liquid culture. This study investigated the value of a quantitative PCR assay for early bactericidal activity determination. Groups of 15 patients were treated with 6 different antituberculosis agents or regimens. Patients collected sputum for 16 h overnight at baseline and at days 7 and 14 after treatment initiation. We determined the sputum bacterial load by CFU counting (log CFU/ml sputum, reported as mean ± standard deviation [SD]), time to culture positivity (TTP, in hours [mean ± SD]) in liquid culture, and Xpert MTB/RIF cycle thresholds (C(T), n [mean ± SD]). The ability to discriminate treatment effects between groups was analyzed with one-way analysis of variance (ANOVA). All measurements showed a decrease in bacterial load from mean baseline (log CFU, 5.72 ± 1.00; TTP, 116.0 ± 47.6; C(T), 19.3 ± 3.88) to day 7 (log CFU, -0.26 ± 1.23, P = 0.2112; TTP, 35.5 ± 59.3, P = 0.0002; C(T), 0.55 ± 3.07, P = 0.6030) and day 14 (log CFU, -0.55 ± 1.24, P = 0.0006; TTP, 54.8 ± 86.8, P < 0.0001; C(T), 2.06 ± 4.37, P = 0.0020). The best discrimination between group effects was found with TTP at day 7 and day 14 (F = 9.012, P < 0.0001, and F = 11.580, P < 0.0001), followed by log CFU (F = 4.135, P = 0.0024, and F = 7.277, P < 0.0001). C(T) was not significantly discriminative (F = 1.995, P = 0.091, and F = 1.203, P = 0.316, respectively). Culture-based methods are superior to PCR for the quantification of early antituberculosis treatment effects in sputum.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23596237      PMCID: PMC3716052          DOI: 10.1128/JCM.03290-12

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  15 in total

1.  Evaluation of the analytical performance of the Xpert MTB/RIF assay.

Authors:  Robert Blakemore; Elizabeth Story; Danica Helb; JoAnn Kop; Padmapriya Banada; Michelle R Owens; Soumitesh Chakravorty; Martin Jones; David Alland
Journal:  J Clin Microbiol       Date:  2010-05-26       Impact factor: 5.948

2.  Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting.

Authors:  Grant Theron; Jonny Peter; Richard van Zyl-Smit; Hridesh Mishra; Elizabeth Streicher; Samuel Murray; Rodney Dawson; Andrew Whitelaw; Michael Hoelscher; Surendra Sharma; Madhukar Pai; Robin Warren; Keertan Dheda
Journal:  Am J Respir Crit Care Med       Date:  2011-04-14       Impact factor: 21.405

3.  Time to liquid culture positivity can substitute for colony counting on agar plates in early bactericidal activity studies of antituberculosis agents.

Authors:  A H Diacon; J S Maritz; A Venter; P D van Helden; R Dawson; P R Donald
Journal:  Clin Microbiol Infect       Date:  2011-08-18       Impact factor: 8.067

4.  Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients.

Authors:  A C Hesseling; G Walzl; D A Enarson; N M Carroll; K Duncan; P T Lukey; C Lombard; P R Donald; K A Lawrence; R P Gie; P D van Helden; N Beyers
Journal:  Int J Tuberc Lung Dis       Date:  2010-05       Impact factor: 2.373

5.  Polymerase chain reaction for assessing treatment response in patients with pulmonary tuberculosis.

Authors:  N Kennedy; S H Gillespie; A O Saruni; G Kisyombe; R McNerney; F I Ngowi; S Wilson
Journal:  J Infect Dis       Date:  1994-09       Impact factor: 5.226

6.  The early bactericidal activity of drugs in patients with pulmonary tuberculosis.

Authors:  A Jindani; V R Aber; E A Edwards; D A Mitchison
Journal:  Am Rev Respir Dis       Date:  1980-06

7.  Rapid molecular detection of tuberculosis and rifampin resistance.

Authors:  Catharina C Boehme; Pamela Nabeta; Doris Hillemann; Mark P Nicol; Shubhada Shenai; Fiorella Krapp; Jenny Allen; Rasim Tahirli; Robert Blakemore; Roxana Rustomjee; Ana Milovic; Martin Jones; Sean M O'Brien; David H Persing; Sabine Ruesch-Gerdes; Eduardo Gotuzzo; Camilla Rodrigues; David Alland; Mark D Perkins
Journal:  N Engl J Med       Date:  2010-09-01       Impact factor: 91.245

8.  Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology.

Authors:  Danica Helb; Martin Jones; Elizabeth Story; Catharina Boehme; Ellen Wallace; Ken Ho; JoAnn Kop; Michelle R Owens; Richard Rodgers; Padmapriya Banada; Hassan Safi; Robert Blakemore; N T Ngoc Lan; Edward C Jones-López; Michael Levi; Michele Burday; Irene Ayakaka; Roy D Mugerwa; Bill McMillan; Emily Winn-Deen; Lee Christel; Peter Dailey; Mark D Perkins; David H Persing; David Alland
Journal:  J Clin Microbiol       Date:  2009-10-28       Impact factor: 5.948

9.  Time to detection of Mycobacterium tuberculosis in BACTEC systems as a viable alternative to colony counting.

Authors:  C Pheiffer; N M Carroll; N Beyers; P Donald; K Duncan; P Uys; P van Helden
Journal:  Int J Tuberc Lung Dis       Date:  2008-07       Impact factor: 2.373

10.  Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay--a clinical validation study.

Authors:  Andrea Rachow; Alimuddin Zumla; Norbert Heinrich; Gabriel Rojas-Ponce; Bariki Mtafya; Klaus Reither; Elias N Ntinginya; Justin O'Grady; Jim Huggett; Keertan Dheda; Catharina Boehme; Mark Perkins; Elmar Saathoff; Michael Hoelscher
Journal:  PLoS One       Date:  2011-06-29       Impact factor: 3.240

View more
  16 in total

Review 1.  Pharmacologic considerations in use and development of antituberculosis drugs.

Authors:  Geraint Davies
Journal:  Cold Spring Harb Perspect Med       Date:  2014-09-18       Impact factor: 6.915

2.  Modeling and Simulation of Pretomanid Pharmacodynamics in Pulmonary Tuberculosis Patients.

Authors:  Michael A Lyons
Journal:  Antimicrob Agents Chemother       Date:  2019-09-30       Impact factor: 5.191

3.  Xpert MTB/RIF as a measure of sputum bacillary burden. Variation by HIV status and immunosuppression.

Authors:  Colleen F Hanrahan; Grant Theron; Jean Bassett; Keertan Dheda; Lesley Scott; Wendy Stevens; Ian Sanne; Annelies Van Rie
Journal:  Am J Respir Crit Care Med       Date:  2014-06-01       Impact factor: 21.405

4.  Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  David J Horne; Mikashmi Kohli; Jerry S Zifodya; Ian Schiller; Nandini Dendukuri; Deanna Tollefson; Samuel G Schumacher; Eleanor A Ochodo; Madhukar Pai; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2019-06-07

5.  Multicenter Evaluation of Anyplex Plus MTB/NTM MDR-TB Assay for Rapid Detection of Mycobacterium tuberculosis Complex and Multidrug-Resistant Isolates in Pulmonary and Extrapulmonary Specimens.

Authors:  Michela Sali; Flavio De Maio; Francesca Caccuri; Federica Campilongo; Maurizio Sanguinetti; Simona Fiorentini; Giovanni Delogu; Cinzia Giagulli
Journal:  J Clin Microbiol       Date:  2015-10-21       Impact factor: 5.948

Review 6.  Nuclear imaging: a powerful novel approach for tuberculosis.

Authors:  Daniel H Johnson; Laura E Via; Peter Kim; Dominick Laddy; Chuen-Yen Lau; Edward A Weinstein; Sanjay Jain
Journal:  Nucl Med Biol       Date:  2014-08-07       Impact factor: 2.408

7.  The molecular bacterial load assay replaces solid culture for measuring early bactericidal response to antituberculosis treatment.

Authors:  Isobella Honeyborne; Bariki Mtafya; Patrick P J Phillips; Michael Hoelscher; Elias N Ntinginya; Anke Kohlenberg; Andrea Rachow; Gabriel Rojas-Ponce; Timothy D McHugh; Norbert Heinrich
Journal:  J Clin Microbiol       Date:  2014-05-28       Impact factor: 5.948

8.  Baseline Xpert MTB/RIF ct values predict sputum conversion during the intensive phase of anti-TB treatment in HIV infected patients in Kampala, Uganda: a retrospective study.

Authors:  Juliet Namugenyi; Joseph Musaazi; Achilles Katamba; Joan Kalyango; Emmanuel Sendaula; Andrew Kambugu; Jan Fehr; Barbara Castelnouvo; Yukari C Manabe; Willy Ssengooba; Christine Sekaggya-Wiltshire
Journal:  BMC Infect Dis       Date:  2021-06-01       Impact factor: 3.090

9.  Chemiluminescent Protease Probe for Rapid, Sensitive, and Inexpensive Detection of Live Mycobacterium tuberculosis.

Authors:  Brett M Babin; Gabriela Fernandez-Cuervo; Jessica Sheng; Ori Green; Alvaro A Ordonez; Mitchell L Turner; Laura J Keller; Sanjay K Jain; Doron Shabat; Matthew Bogyo
Journal:  ACS Cent Sci       Date:  2021-04-14       Impact factor: 14.553

Review 10.  PET/CT imaging of Mycobacterium tuberculosis infection.

Authors:  Alfred O Ankrah; Tjip S van der Werf; Erik F J de Vries; Rudi A J O Dierckx; Mike M Sathekge; Andor W J M Glaudemans
Journal:  Clin Transl Imaging       Date:  2016-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.